Clinical Trial

Genitourinary Tumors With Sacituzumab Tirumotecan

Study acronym: RINGQUEST
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
RINGQUEST is a Phase 2, open-label, single arm, basket, investigator-initiated clinical trial of sacituzumab tirumotecan in patients with: * Cohort 1: papillary renal carcinoma (pRCC). * Cohort 2: less frequent bladder tumors such as variant histology urothelial carcinoma (VH-UC). The most common VH-UC are nested, microcystic, micropapillary, lymphoepithelioma-like, plasmacytoid, giant cell, poorly differentiated, lipid-rich, clear cell, sarcomatoid) bladder cancer and non-urothelial bladder cancer of epithelial origin including squamous cell carcinoma and adenocarcinoma (urachal and non-urachal).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-07-16.
Trial Details
NCT Number NCT07716917
Lead Sponsor Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD
Collaborators: Merck Sharp & Dohme LLC, MFAR
Conditions Papillary Renal Carcinoma, Variant Histology Urothelial Carcinoma
Enrollment 100 participants
Start Date 2026-10
Primary Completion 2029-10 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-23